Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Nov;24(5):661–664. doi: 10.1111/j.1365-2125.1987.tb03226.x

Pharmacokinetics and pharmacodynamics of two formulations of verapamil.

K K Hla 1, J A Henry 1, A N Latham 1
PMCID: PMC1386339  PMID: 3435694

Abstract

The pharmacokinetics and pharmacodynamics of sustained release verapamil were compared with the conventional formulation in 10 healthy adult volunteers after single and multiple dosing. The mean time of maximum plasma concentrations of verapamil were significantly prolonged and the absorption rate constants significantly reduced after sustained release verapamil on both day 1 and day 10. On day 10 there was no significant difference between formulations in the relative bioavailability of verapamil. However, the area under the plasma concentration-time curve and maximum concentration (Cmax) for both formulations increased significantly with repeat dosing. On day 10, the difference in Cmax between formulations was significant. The day 10 mean peak/trough plasma verapamil concentration ratio was significantly less following the sustained release dose form. The mean PR interval was significantly prolonged by both formulations on day 1 and day 10. There were no differences between formulations other than a significantly longer PR interval following the conventional formulation 2 h after dosing on day 10.

Full text

PDF
661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Bondesson U., Sylvén C., Aström H. Plasma concentration--response relationship of verapamil in the treatment of angina pectoris. J Cardiovasc Pharmacol. 1982 Jul-Aug;4(4):609–614. doi: 10.1097/00005344-198207000-00012. [DOI] [PubMed] [Google Scholar]
  2. Cole S. C., Flanagan R. J., Johnston A., Holt D. W. Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr. 1981 Nov 20;218:621–629. doi: 10.1016/s0021-9673(00)82087-7. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M., Somogyi A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol. 1984;26(1):47–53. doi: 10.1007/BF00546708. [DOI] [PubMed] [Google Scholar]
  4. Freedman S. B., Richmond D. R., Ashley J. J., Kelly D. T. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther. 1981 Nov;30(5):644–652. doi: 10.1038/clpt.1981.216. [DOI] [PubMed] [Google Scholar]
  5. Guissou P., Cuisinaud G., Llorca G., Lejeune E., Sassard J. Chronopharmacokinetic study of a prolonged release form of indomethacin. Eur J Clin Pharmacol. 1983;24(5):667–670. doi: 10.1007/BF00542219. [DOI] [PubMed] [Google Scholar]
  6. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  7. McAllister R. G., Jr, Kirsten E. B. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):418–426. doi: 10.1038/clpt.1982.54. [DOI] [PubMed] [Google Scholar]
  8. Pozenel H. Die antihypertensive Wirkung von Verapamil. Ergebnisse mit einer neuen Retardform zur Einmaldosierung. Fortschr Med. 1985 Jun 20;103(23):639–642. [PubMed] [Google Scholar]
  9. Schomerus M., Spiegelhalder B., Stieren B., Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res. 1976 Sep;10(5):605–612. doi: 10.1093/cvr/10.5.605. [DOI] [PubMed] [Google Scholar]
  10. Schwartz J. B., Abernethy D. R., Taylor A. A., Mitchell J. R. An investigation of the cause of accumulation of verapamil during regular dosing in patients. Br J Clin Pharmacol. 1985 Apr;19(4):512–516. doi: 10.1111/j.1365-2125.1985.tb02678.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schwartz J. B., Keefe D. L., Kirsten E., Kates R. E., Harrison D. C. Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J. 1982 Aug;104(2 Pt 1):198–203. doi: 10.1016/0002-8703(82)90192-2. [DOI] [PubMed] [Google Scholar]
  12. Shand D. G., Hammill S. C., Aanonsen L., Pritchett E. L. Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther. 1981 Nov;30(5):701–706. doi: 10.1038/clpt.1981.223. [DOI] [PubMed] [Google Scholar]
  13. Woodcock B. G., Kraemer N., Rietbrock N. Effect of a high protein meal on the bioavailability of verapamil. Br J Clin Pharmacol. 1986 Mar;21(3):337–338. doi: 10.1111/j.1365-2125.1986.tb05202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Woodcock B. G., Rietbrock I., Vöhringer H. F., Rietbrock N. Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther. 1981 Jan;29(1):27–34. doi: 10.1038/clpt.1981.5. [DOI] [PubMed] [Google Scholar]
  15. Woodcock B. G., Schulz W., Kober G., Rietbrock N. Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther. 1981 Jul;30(1):52–56. doi: 10.1038/clpt.1981.126. [DOI] [PubMed] [Google Scholar]
  16. Zachariah P. K., Sheps S. G., Schirger A., Spiekerman R. E., O'Brien P. C., Simpson K. K. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Am J Cardiol. 1986 Feb 26;57(7):74D–79D. doi: 10.1016/0002-9149(86)90811-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES